Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 11/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | KLK7 | P49862 | 2/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13657954 | 0.82 | RORC (0.47) | RORCJAK2JAK1OPRD1OPRK1 | |
| SCHEMBL3914620 | 0.81 | RORC (0.43) | RORCJAK2JAK1OPRD1OPRK1 | |
| SCHEMBL3914621 | 0.81 | RORC (0.43) | RORCJAK2JAK1OPRD1OPRK1 | |
| SCHEMBL3922516 | 0.80 | RORC (0.43) | RORCJAK2JAK1OPRD1OPRK1 | |
| SCHEMBL3922509 | 0.80 | RORC (0.43) | RORCJAK2JAK1OPRD1OPRK1 | |
| SCHEMBL4156484 | 0.79 | CYP3A4 (0.47) | OPRD1L3MBTL1LMNA | |
| SCHEMBL4156493 | 0.79 | CYP3A4 (0.47) | OPRD1L3MBTL1LMNA | |
| SCHEMBL3919294 | 0.76 | JAK2 (0.43) | RORCJAK2JAK1GPR119KLK7 | |
| SCHEMBL3922323 | 0.76 | JAK2 (0.43) | RORCJAK2JAK1GPR119KLK7 | |
| SCHEMBL25107740 | 0.73 | NPFFR1 (0.43) | OPRD1L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247577-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | ROGEL OLIVIER | 2009-10-01 | — | — | US | disclosed |
| US-20090247577-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | ROGEL OLIVIER | 2009-10-01 | — | — | US | disclosed |
| WO-2007140980-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247577-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | BACE1, BACE2, APP | RORC 3624/4885JAK2 3614/4885JAK1 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.